Emerging Technology
BJ Bioscience Announces Clinical Collaboration With MSD To Evaluate BJ-001 In Combination With KEYTRUDA (pembrolizumab)
By PR Newswire
SHANGHAI, March 27, 2023 /PRNewswire/ -- BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today announced that it entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). The collaboration will allow for the evaluation of safety and efficacy of BJ-001, a tumor-targeting IL-15 fusion protein, in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in an ongoing Phase 1 clinical trial.
BJ Bioscience will evaluate BJ-001 plus KEYTRUDA as part of the company's ongoing trial in patients with locally advanced/metastatic solid tumors. In this trial, BJ-001 is studied as monotherapy or in combination with KEYTRUDA, for safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity.
In monotherapy dose escalation cohorts, BJ-001 has demonstrated tolerable safety profiles, favorable PK/PD profiles, and encouraging preliminary efficacy results.
"BJ Bioscience is excited to collaborate with MSD, one of the world's leading multinational pharmaceutical companies," said Joe Zhang, MD, PhD, cofounder and CEO of BJ Bioscience. "Many consider KEYTRUDA to be one of the gold-standard medicines in the cancer immunotherapy arena. We believe BJ-001 may be a promising addition to this area. Our preclinical studies demonstrated that the combination of BJ-001 and an anti-PD-1 antibody was well-tolerated and showed promising early antitumor activity compared to either drug alone as monotherapy. With its tumor-targeting properties, we're looking forward to evaluating BJ-001 in combination with KEYTRUDA as a potential new treatment option to benefit more cancer patients. This investigational combination is a key component of our BJ-001 development program."
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About BJ-001
BJ-001 is a tumor-targeting IL-15 fusion protein, designed to expand and activate cancer-fighting natural killer (NK) cells and CD8+ T cells, and to have selected distribution in tumors with high integrin-expression. Preclinical data have demonstrated the ability of BJ-001 to accumulate in integrin-expressing tumors. Clinical data to date have shown Best-in-Class properties of BJ-001, including tolerable safety, dose-dependent and encouraging magnitude of stimulation and expansion of NK cells and CD8+ T cells with no impact on immunosuppressive regulatory T cells.
About BJ Bioscience, Inc.
BJ Bioscience Inc. is a clinical stage biotech company creating next generation of immunotherapies for cancer, inflammation and autoimmunity using its trade secret protected antibody discovery and screening technology and SIB® bispecific antibody platform. BJ Bioscience's lead asset, BJ-001, is in Phase 1 clinical studies in the US and China. For more information, please visit the BJ Bioscience website: www.bjbioscience.com.
Contacts:
Media
bjbio@bjbioscience.com
Investors
joe.zhang@bjbioscience.com
View original content:https://www.prnewswire.com/news-releases/bj-bioscience-announces-clinical-collaboration-with-msd-to-evaluate-bj-001-in-combination-with-keytruda-pembrolizumab-301782741.html
SOURCE BJ Bioscience Inc.
First published on Tue, Mar 28, 2023
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Amwins Acquires Superior Underwriters
By PR Newswire
Ceva Unveils Ceva-Waves Links200 - A Breakthrough Multi-Protocol Wireless Connectivity Platform IP Featuring Next Generation Bluetooth High Data Throughput (HDT) And IEEE 802.15.4
By PR Newswire
Dayone Launches As An Independent Global Data Center Pioneer Following Series B Funding Closure
By PR Newswire
Eco-Movement Boosts EV Charging Data Innovation With Acquisition From EVA Global
By PR Newswire
Kucoin Launches Kucoin Pay, A Merchant Solution Leading The Future Of Crypto Payments
By PR Newswire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion